Summit Hotel Properties, Inc. (INN)
After hours:
| Previous Close | 6.25 |
| Open | 6.29 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 2900 |
| Day's Range | 6.20 - 6.31 |
| 52 Week Range | 5.31 - 7.26 |
| Volume | |
| Avg. Volume | 763,250 |
| Market Cap | 670.79M |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.32 (5.16%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | N/A |
- PR Newswire
SUMMIT HOTEL PROPERTIES REPORTS FIRST QUARTER 2024 RESULTS
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company"), today announced results for the three months ended March 31, 2024.
- CNW Group
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
- CNW Group
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023.
